TTNP vs. CELZ, FRTX, PALI, TCON, FNCH, KRBP, SRNE, GENE, ALBT, and ELOX
Should you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Creative Medical Technology (CELZ), Fresh Tracks Therapeutics (FRTX), Palisade Bio (PALI), TRACON Pharmaceuticals (TCON), Finch Therapeutics Group (FNCH), Kiromic BioPharma (KRBP), Sorrento Therapeutics (SRNE), Genetic Technologies (GENE), Avalon GloboCare (ALBT), and Eloxx Pharmaceuticals (ELOX). These companies are all part of the "biological products, except diagnostic" industry.
Titan Pharmaceuticals (NASDAQ:TTNP) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability.
Titan Pharmaceuticals received 264 more outperform votes than Creative Medical Technology when rated by MarketBeat users. However, 68.93% of users gave Creative Medical Technology an outperform vote while only 57.17% of users gave Titan Pharmaceuticals an outperform vote.
Titan Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.
Creative Medical Technology has higher revenue and earnings than Titan Pharmaceuticals. Creative Medical Technology is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 24.9% of Titan Pharmaceuticals shares are owned by company insiders. Comparatively, 3.3% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Titan Pharmaceuticals and Titan Pharmaceuticals both had 1 articles in the media. Creative Medical Technology's average media sentiment score of 0.67 beat Titan Pharmaceuticals' score of 0.25 indicating that Creative Medical Technology is being referred to more favorably in the news media.
Creative Medical Technology has a net margin of 0.00% compared to Titan Pharmaceuticals' net margin of -2,014.71%. Creative Medical Technology's return on equity of -41.48% beat Titan Pharmaceuticals' return on equity.
Summary
Creative Medical Technology beats Titan Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Titan Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Titan Pharmaceuticals Competitors List
Related Companies and Tools
